ConAgra Brands, Inc. – Consensus Indicates Potential 4.8% Upside

DirectorsTalk Interviews

ConAgra Brands, Inc. with ticker code (CAG) now have 14 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 40 and 32 with the average target price sitting at 35.96. With the stocks previous close at 34.32 this now indicates there is a potential upside of 4.8%. The 50 day moving average now sits at 34.48 and the 200 moving average now moves to 33.97. The company has a market cap of $16,519m. You can visit the company’s website by visiting: https://www.conagrabrands.com

The potential market cap would be $17,309m based on the market concensus.

Conagra Brands, Inc., together with its subsidiaries, operates as a consumer packaged goods food company in North America. The company operates in four segments: Grocery & Snacks, Refrigerated & Frozen, International, and Foodservice. The Grocery & Snacks segment primarily offers shelf stable food products through various retail channels in the United States. The Refrigerated & Frozen segment provides temperature-controlled food products through various retail channels in the United States. The International segment offers food products in various temperature states through retail and foodservice channels outside of the United States. The Foodservice segment offers branded and customized food products, including meals, entrees, sauces, and various custom-manufactured culinary products packaged for restaurants and other foodservice establishments in the United States. The company sells its products under the Birds Eye, Duncan Hines, Healthy Choice, Marie Callender’s, Reddi-wip, Slim Jim, Angie’s BOOMCHICKAPOP, Duke’s, Earth Balance, Gardein, and Frontera brands. The company was formerly known as ConAgra Foods, Inc. and changed its name to Conagra Brands, Inc. in November 2016. Conagra Brands, Inc. was founded in 1861 and is headquartered in Chicago, Illinois.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search